{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:57:24Z","timestamp":1789685844412,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jbo.2023.100470","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T01:26:17Z","timestamp":1675905977000},"page":"100470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-7661","authenticated-orcid":false,"given":"Justin-Pierre","family":"Lorange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ramirez Garcia Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Grou-Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Akoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jbo.2023.100470_b0005","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.drudis.2014.08.007","article-title":"An analysis of FDA-approved drugs for oncology","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0010","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"1\u20132","key":"10.1016\/j.jbo.2023.100470_b0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1615\/CritRevOncog.v18.i1-2.40","article-title":"On the origin of cancer metastasis","volume":"18","author":"Seyfried","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-016-3857-1","article-title":"The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases","volume":"158","author":"Dillek\u00e5s","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2023.100470_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jocn.2016.05.023","article-title":"Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: helping surgeons make decisions","volume":"34","author":"Batista","year":"2016","journal-title":"J. Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.jbo.2023.100470_b0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/2192568217710911","article-title":"Systematic review of the outcomes of surgical treatment of prostate metastases to the spine","volume":"7","author":"Clarke","year":"2017","journal-title":"Global Spine J."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"10.1016\/j.jbo.2023.100470_b0040","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jbo.2023.100470_b0045","first-page":"1029","article-title":"Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Menshawy","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2023.100470_b0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2019.05.013","article-title":"Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: a 12-year longitudinal nationwide healthcare database study","volume":"61","author":"Baek","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"8","key":"10.1016\/j.jbo.2023.100470_b0055","first-page":"879","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2023.100470_b0060","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur. J. Cancer Care (Engl.)"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13046-017-0578-1","article-title":"Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials","volume":"36","author":"Gdowski","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2023.100470_b0070","doi-asserted-by":"crossref","unstructured":"Gonzalez BD, Brownstein NC, Fan W, Dicker AP, Oswald LB, Dhillon HM, et al. Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer. Journal of Clinical Oncology. 2022;40(6_suppl):96-.","DOI":"10.1200\/JCO.2022.40.6_suppl.096"},{"issue":"9","key":"10.1016\/j.jbo.2023.100470_b0075","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jbo.2023.100470_b0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Di Salvatore","year":"2011","journal-title":"Cell Prolif."},{"issue":"6","key":"10.1016\/j.jbo.2023.100470_b0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.biopha.2013.04.006","article-title":"STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells","volume":"67","author":"Kiper","year":"2013","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.jbo.2023.100470_b0090","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s10616-015-9884-7","article-title":"Zoledronic acid suppresses metastasis of esophageal squamous cell carcinoma cells through upregulating the tight junction protein occludin","volume":"68","author":"Lin","year":"2016","journal-title":"Cytotechnology"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2004.06.003","article-title":"Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines","volume":"47","author":"Matsumoto","year":"2005","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2023.100470_b0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tripleo.2010.09.068","article-title":"Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis","volume":"111","author":"Reuben","year":"2011","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"issue":"9","key":"10.1016\/j.jbo.2023.100470_b0105","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2023.100470_b0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-642-21892-7_3","article-title":"Bisphosphonates: prevention of bone metastases in breast cancer","volume":"192","author":"Gnant","year":"2012","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.jbo.2023.100470_b0115","doi-asserted-by":"crossref","unstructured":"Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, et al. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist. 2015;20(4):440-9.","DOI":"10.1634\/theoncologist.2014-0328"},{"issue":"2","key":"10.1016\/j.jbo.2023.100470_b0120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2023.100470_b0125","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.jbo.2023.100470_b0135","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.jbo.2023.100470_b0145","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis in R: A hands-on guide. PROTECT Lab Erlangen. 2019."},{"key":"10.1016\/j.jbo.2023.100470_b0150","unstructured":"Foundation TR. The R Project for Statistical Computing 2020 [cited 2021 March 6th]. Available from: https:\/\/www.r-project.org."},{"issue":"3","key":"10.1016\/j.jbo.2023.100470_b0155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/0973-1075.92338","article-title":"A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis","volume":"17","author":"Choudhury","year":"2011","journal-title":"Indian J. Palliat. Care"},{"issue":"5","key":"10.1016\/j.jbo.2023.100470_b0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1525-7304(11)70347-3","article-title":"Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases","volume":"5","author":"Price","year":"2004","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0165","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","article-title":"Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial","volume":"13","author":"Broom","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"issue":"9768","key":"10.1016\/j.jbo.2023.100470_b0175","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jbo.2023.100470_b0180","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10147-010-0179-x","article-title":"Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer","volume":"16","author":"Francini","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2023.100470_b0185","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2023.100470_b0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbo.2017.11.001","article-title":"Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer","volume":"10","author":"Hilton","year":"2018","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-015-3646-2","article-title":"A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer","volume":"155","author":"Jacobs","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"53","key":"10.1016\/j.jbo.2023.100470_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20530","article-title":"TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer","volume":"20","author":"James","year":"2016","journal-title":"Health Technol. Assess."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0205","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.jbo.2023.100470_b0210","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2023.100470_b0215","doi-asserted-by":"crossref","unstructured":"Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18(17):4841-9.","DOI":"10.1158\/1078-0432.CCR-11-3310"},{"issue":"8","key":"10.1016\/j.jbo.2023.100470_b0220","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cas.12448","article-title":"Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group","volume":"105","author":"Murakami","year":"2014","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.jbo.2023.100470_b0225","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s11255-014-0824-9","article-title":"Docetaxel with or without zoledronic acid for castration-resistant prostate cancer","volume":"46","author":"Pan","year":"2014","journal-title":"Int. Urol. Nephrol."},{"issue":"8","key":"10.1016\/j.jbo.2023.100470_b0230","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2023.100470_b0235","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.jbo.2023.100470_b0240","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jbo.2023.100470_b0245","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2023.100470_b0250","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.jbo.2023.100470_b0255","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jbo.2023.100470_b0260","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"33","author":"Ueno","year":"2013","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.jbo.2023.100470_b0265","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-013-0657-x","article-title":"Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases","volume":"30","author":"Wang","year":"2013","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2023.100470_b0270","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2023.100470_b0275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cllc.2012.09.001","article-title":"Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer","volume":"14","author":"Wang","year":"2013","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2023.100470_b0280","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.lungcan.2009.04.020","article-title":"Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer","volume":"67","author":"Pandya","year":"2010","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/TCRM.S2707","article-title":"Zoledronic acid in the management of metastatic bone disease","volume":"4","author":"Polascik","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.jbo.2023.100470_b0290","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2023.100470_b0295","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.clinthera.2020.05.019","article-title":"Denosumab versus zoledronic acid in the prevention of skeletal-related events in vulnerable cancer patients: a meta-analysis of randomized","volume":"42","author":"Chen","year":"2020","journal-title":"Controlled Trials. Clinical Therapeutics."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0300","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials","volume":"16","author":"Jiang","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"issue":"5","key":"10.1016\/j.jbo.2023.100470_b0305","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s00223-022-01011-w","article-title":"Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral fractures in women with breast cancer undergoing treatment with aromatase inhibitors","volume":"111","author":"Mazziotti","year":"2022","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"10.1016\/j.jbo.2023.100470_b0310","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","article-title":"Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases","volume":"17","author":"Botteman","year":"2006","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.jbo.2023.100470_b0315","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (alliance)","volume":"35","author":"Shapiro","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2023.100470_b0320","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0325","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int."},{"issue":"17","key":"10.1016\/j.jbo.2023.100470_b0330","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2023.100470_b0335","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION- ZOMETA New Jersey: Novartis Pharmaceuticals Corporation; 2016 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021223s034lbl.pdf."},{"key":"10.1016\/j.jbo.2023.100470_b0340","article-title":"Population Pharmacokinetics (PK) of Zometa","author":"Berenson","year":"2000","journal-title":"Proc ASCO"},{"issue":"9","key":"10.1016\/j.jbo.2023.100470_b0345","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/ma11091485","article-title":"Nanoporous 3D-printed scaffolds for local doxorubicin delivery in bone metastases secondary to prostate cancer","volume":"11","author":"Ahangar","year":"2018","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.jbo.2023.100470_b0350","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jbo.2017.01.001","article-title":"Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration","volume":"6","author":"Nooh","year":"2017","journal-title":"J. Bone Oncol."},{"issue":"21","key":"10.1016\/j.jbo.2023.100470_b0355","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1557\/adv.2019.156","article-title":"3D-printed nanoporous scaffolds impregnated with zoledronate for the treatment of spinal bone metastases","volume":"4","author":"Akoury","year":"2019","journal-title":"MRS Adv."},{"issue":"2","key":"10.1016\/j.jbo.2023.100470_b0360","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles:applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jbo.2023.100470_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.654518","article-title":"A composite lactide-mineral 3D-printed scaffold for bone repair and regeneration","volume":"9","author":"Fairag","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.jbo.2023.100470_b0370","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3892\/ijo.2013.1809","article-title":"Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines Corrigendum in\/10.3892\/ijo.2016.3613","volume":"42","author":"Ibrahim","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2023.100470_b0375","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12885-018-4412-8","article-title":"PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2023.100470_b0380","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137423000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137423000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:54Z","timestamp":1761941994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137423000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":76,"alternative-id":["S2212137423000039"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2023.100470","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2023.100470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100470"}}